Cabot
CABOT CORP
Key figures
Period Oct 2024 to Sep 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$3.7B
Operating marginCalculated
16.7%
Net assets to total assetsCalculated
40.6%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
16.7%
Growth (revenue, 4-year average)
★★☆☆☆position among all companies
2.2%
Capital efficiency
★★★★☆position among all companies
21.4%
Revenue and profit
Performance, financial position and capital allocation
Cabot
Recent performance trends
Cabot
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$3.4 billion | US$4.3 billion | US$3.9 billion | US$4.0 billion | US$3.7 billion |
| Operating income | US$0.5 billion | US$0.4 billion | US$0.5 billion | US$0.6 billion | US$0.6 billion |
| Net income | US$0.2 billion | US$0.2 billion | US$0.4 billion | US$0.4 billion | US$0.3 billion |
| Total assets | US$3.3 billion | US$3.5 billion | US$3.6 billion | US$3.7 billion | US$3.8 billion |
| Shareholders' equity | US$0.9 billion | US$0.9 billion | US$1.3 billion | US$1.4 billion | US$1.6 billion |
| Net cash provided by (used in) operating activities | US$0.3 billion | US$0.1 billion | US$0.6 billion | US$0.7 billion | US$0.7 billion |
| Net cash provided by (used in) investing activities | US$-0.2 billion | US$-0.1 billion | US$-0.2 billion | US$-0.2 billion | US$-0.3 billion |
| Net cash provided by (used in) financing activities | US$-60.00 million | US$0.1 billion | US$-0.4 billion | US$-0.4 billion | US$-0.3 billion |
| Cash and cash equivalents | US$0.2 billion | US$0.2 billion | US$0.2 billion | US$0.2 billion | US$0.3 billion |
Revenue scale in the same industry
Cabot
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 44 companies
- 48 Solstice Advanced MaterialsFY Dec 2025 US$3.9B
- 49 Alnylam PharmaceuticalsFY Dec 2025 US$3.7B
- 50 CabotThis companyFY Sep 2025 US$3.7B
- 51 Fuller H BFY Nov 2025 US$3.5B
- 52 FMCFY Dec 2025 US$3.5B
- … 4 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.3 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.7 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.2 billion | Consolidated | Disclosed |
| Dividends paid | US$96.00 million | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$1.7 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.2 billion | Consolidated | Disclosed |
| Net assets | US$1.6 billion | Consolidated | Disclosed |
| Net sales | US$3.7 billion | Consolidated | Disclosed |
| Operating income | US$0.6 billion | Consolidated | Disclosed |
| Net income | US$0.3 billion | Consolidated | Disclosed |
| Total assets | US$3.8 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.2 billion | Consolidated | Disclosed |
| Operating margin | 16.7% | Consolidated | Calculated |
| Net assets to total assets | 40.6% | Consolidated | Calculated |
| Net margin | 8.9% | Consolidated | Calculated |
| Return on equity | 21.4% | Consolidated | Calculated |